Angiex Doses First Patients in AGX101 ADC Trial

The Phase 1 clinical study of AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC), has started patient dosing, according to Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapeutics for solid tumours. Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, and Angiex collaborated to assist the study's development, production, and supply of clinical trial materials.

With three different modes of action, AGX101 targets the tumor's two compartments—cancer cells and the tumour vasculature—by destroying tumour cells that can invade and spread, blocking tumour blood vessels, and stimulating the immune system to combat the disease. With an integrated program including linker-payload design and synthesis, bioconjugation, process development, and cGMP manufacturing for Angiex's Phase 1 trial, Abzena has provided support for the development of AGX101. The Phase 1 trial aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor efficacy of AGX101 monotherapy. It is an open-label, dose-escalation, and expansion research.